StockWatch
·
Biotechnology: Pharmaceutical Preparations
USFDANov 20, 2026, 08:02 AM

Annovis Bio: FDA Agrees to Pool Safety Data for Buntanetap NDA

AI Summary

Annovis Bio, Inc. announced that the FDA has agreed to its Integrated Summary of Safety (ISS) plan for buntanetap. This plan involves pooling safety data from four ongoing and completed Alzheimer's and Parkinson's clinical studies. The company will integrate this pooled data at the level of standardized analysis datasets to support its planned New Drug Application (NDA). Annovis anticipates over 1,600 participants will have received buntanetap across the pooled studies by the 6-month data readout from the DUET-AD study. The NDA submission is planned after the DUET-AD data readout.

Key Highlights

  • FDA agrees with Annovis Bio's plan to pool safety data from four Alzheimer's and Parkinson's studies for buntanetap.
  • Pooled safety data will be integrated at the level of standardized analysis datasets.
  • NDA submission for buntanetap is planned after the DUET-AD data readout.
  • Over 1,600 participants expected to have received buntanetap across pooled studies by DUET-AD 6-month readout.
  • The pooled analysis includes three randomized, double-blind, placebo-controlled studies and one open-label extension study.